ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin) | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.
MENU

ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)
Peptide News from Biotech and Pharma, Raw News September 17, 2017

LEUVEN, Belgium I September 18, 2017 I ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for ...

Email

support@boulderpeptide.org

s2Member®
loading...